All United for MG has opened a petition in Europe supporting myasthenia gravis (MG) patient and caregiver rights, including…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
A treatment course of low-dose rituximab eased measures of clinical severity, improved quality of life, and allowed lower steroid…
Myasthenia gravis (MG) patients on long-term treatment with intravenous immunoglobulin (IVIg) or nonsteroidal immunosuppressants have significantly higher rates…
Vyvgart (efgartigimod) generally is safe and leads to both significant symptom reductions and improvements in function in people with…
Myasthenia gravis (MG) caused by the presence of self-reactive antibodies targeting muscle-specific kinase (MuSK) affects mostly women in Japan,…
Among people with myasthenia gravis (MG) living in Australia, women and seronegative patients — those whose tests fail to…
A 44-year-old woman positive for the human immunodeficiency virus (HIV) developed myasthenia gravis (MG) after receiving treatment with antiretroviral…
More than half of myasthenia gravis (MG) patients take more than a year to be diagnosed from symptom onset…
Vyvgart (efgartigimod alfa) has been approved in China as an add-on to standard therapy for adults with generalized myasthenia gravis…
The single breath count test (SBCT), a noninvasive and inexpensive pulmonary function test, may help evaluate respiratory function and identify…